Member Info for Babbler2

AVCT has a market capitalisation of just £26.2m which is way below the investment needed to get the company where it is today. Moreover, in the context of this deal, the current value represents an enormous opportunity that the market is totally overlooking. This deal looks set to be a wake-up call for the market.

AVCT has attracted diverse partners in a broad range of applications, targets and areas, which once again, provides grounds for the flexibility of the Affimer platform. We also believe that discussions are on-going for additional partnerships.

Given the potential size of this first significant deal, we believe that it is time the market started to wake up to the long-term value of AVCT’s Affimer technology.

PS - Market will be in jitters today over the vote tomorrow. Yes they have known for a while but it tends to be lastminute.com.

Was hovering over the buy butting to buy more mtmy this morning but didn't... still happy with my 8p average.
ALM tempting - 60p strong support and my av is 65 there.
AVCT filling orders before next push up? Who knows but seems in a much much better position than it was when at 68p and can get them just below 30? Hmmm...

Not ramping just discussing. DYOR do not buy anything I do ;)

It's an illiquid share with low freefloat. Some grabbed a bargain this morning it seems. My AV is 8p. Gl.

Hardman & Co: Wake-up call for the market

Avacta (AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant technical and commercial benefits of Affimers are being recognised increasingly through corporate and academic interest, ongoing evaluations, and deal flow. AVCT has just concluded an Affimer therapeutics development and commercial agreement with the global pharma company, LG Chem, worth up to $310m in upfront and milestone payments. This represents a huge endorsement of the Affimer platform.

Please click here for the full report:

marine sold that one last week as got fed up... guess he did right thing.

took some of the top riser on the dip... $180m dollar partnership mcap a lot lower.

Decided to dip toe in took some just below 30 down as sell.

Not in but buys have been at bid all morning as been getting live quotes. Now they are below bid at 29.97 to buy.

My guess is that's your buy target. Gl and if it gets there I will be buying more too.

nope... not possible imo... the market couldn't possibly have known.

Almost sounds like some of you are taking pleasure in this.... nice. Hope you have a merry Christmas!

How much should this add to the MCAP? Seems its close to year low right now?

Kettle boiled for 2nd time mate... up early :(.

Going to be more "under the radar" as seems some are getting offended by my posts / taking things too seriously. IMO amer is worth a look today... early. As well as BST VAL and SLN. NAI DYOR Im not ramping.

What can I do to lower myself in the ramp rankings? lol.

Which part of "independent" did you not understand?

In addition to the independent analysis, the pharmacokinetics information collected from the clinical evaluation of ValiRx's more recent patients, shows that ValiRx is addressing the protocol's primary and secondary endpoints - as well as all the exploratory tertiary end points

morning all - todays top risers will be :
VAL
AMER
SLN

Imo.

impressive. Glad it worked out for all who had faith here. Hope the price rises significantly for you all :)

well done all:

"significantly exceeded our expectations "